CN1191848C - Chinese medicine prepn for treating throat diseases and stomatopathy and its prepn process - Google Patents
Chinese medicine prepn for treating throat diseases and stomatopathy and its prepn process Download PDFInfo
- Publication number
- CN1191848C CN1191848C CNB021573786A CN02157378A CN1191848C CN 1191848 C CN1191848 C CN 1191848C CN B021573786 A CNB021573786 A CN B021573786A CN 02157378 A CN02157378 A CN 02157378A CN 1191848 C CN1191848 C CN 1191848C
- Authority
- CN
- China
- Prior art keywords
- weight portion
- chinese medicine
- fructus
- adds
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 201000010099 disease Diseases 0.000 title claims abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 23
- 239000003814 drug Substances 0.000 title claims description 49
- 238000000034 method Methods 0.000 title claims description 8
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 claims abstract description 35
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 11
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 7
- 235000009815 Momordica Nutrition 0.000 claims abstract 3
- 241000218984 Momordica Species 0.000 claims abstract 3
- 210000000214 mouth Anatomy 0.000 claims description 39
- 241000219109 Citrullus Species 0.000 claims description 34
- 239000013078 crystal Substances 0.000 claims description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 22
- 239000000047 product Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 10
- 239000006188 syrup Substances 0.000 claims description 9
- 235000020357 syrup Nutrition 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 239000007888 film coating Substances 0.000 claims description 4
- 238000009501 film coating Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 238000000465 moulding Methods 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 230000003068 static effect Effects 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000006189 buccal tablet Substances 0.000 claims description 3
- 229940046011 buccal tablet Drugs 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000013355 food flavoring agent Nutrition 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229940023488 pill Drugs 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000013599 spices Nutrition 0.000 claims description 2
- 241001633583 Adenophora Species 0.000 claims 2
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 claims 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 241000202807 Glycyrrhiza Species 0.000 claims 1
- 235000014435 Mentha Nutrition 0.000 claims 1
- 241001072983 Mentha Species 0.000 claims 1
- 230000036407 pain Effects 0.000 abstract description 16
- 208000002193 Pain Diseases 0.000 abstract description 15
- 206010011224 Cough Diseases 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 10
- 201000007100 Pharyngitis Diseases 0.000 abstract description 7
- 230000008961 swelling Effects 0.000 abstract description 5
- 206010068319 Oropharyngeal pain Diseases 0.000 abstract description 3
- 208000016150 acute pharyngitis Diseases 0.000 abstract description 3
- 238000001228 spectrum Methods 0.000 abstract description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 abstract description 2
- 206010006326 Breath odour Diseases 0.000 abstract description 2
- 206010013952 Dysphonia Diseases 0.000 abstract description 2
- 208000032139 Halitosis Diseases 0.000 abstract description 2
- 201000008197 Laryngitis Diseases 0.000 abstract description 2
- 208000003251 Pruritus Diseases 0.000 abstract description 2
- 201000010550 acute laryngitis Diseases 0.000 abstract description 2
- 206010013781 dry mouth Diseases 0.000 abstract description 2
- 230000007803 itching Effects 0.000 abstract description 2
- 229940041616 menthol Drugs 0.000 abstract description 2
- 230000001846 repelling effect Effects 0.000 abstract description 2
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 241001412627 Adenophora liliifolia Species 0.000 abstract 1
- 244000241235 Citrullus lanatus Species 0.000 abstract 1
- 241000675108 Citrus tangerina Species 0.000 abstract 1
- 206010013789 Dry throat Diseases 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 229930195210 Ophiopogon Natural products 0.000 abstract 1
- 244000248557 Ophiopogon japonicus Species 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 239000010642 eucalyptus oil Substances 0.000 abstract 1
- 229940044949 eucalyptus oil Drugs 0.000 abstract 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 abstract 1
- 208000027498 hoarse voice Diseases 0.000 abstract 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 abstract 1
- 208000030194 mouth disease Diseases 0.000 abstract 1
- 235000019477 peppermint oil Nutrition 0.000 abstract 1
- 210000000867 larynx Anatomy 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 19
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 14
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 7
- 229910021529 ammonia Inorganic materials 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000628997 Flos Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000000114 Pain Threshold Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 210000000436 anus Anatomy 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000037040 pain threshold Effects 0.000 description 3
- 210000004303 peritoneum Anatomy 0.000 description 3
- 231100000245 skin permeability Toxicity 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 2
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 101100006584 Mus musculus Clnk gene Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229960003291 chlorphenamine Drugs 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960003699 evans blue Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- -1 paster Substances 0.000 description 2
- 235000010603 pastilles Nutrition 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 229940102535 prednisone 20 mg Drugs 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 206010002953 Aphonia Diseases 0.000 description 1
- 241000499489 Castor canadensis Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018286 Gingival pain Diseases 0.000 description 1
- 206010018291 Gingival swelling Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 244000283207 Indigofera tinctoria Species 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 235000011779 Menyanthes trifoliata Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000010231 banlangen Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229960001660 histamine phosphate Drugs 0.000 description 1
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention discloses a Chinese medical preparation for preventing and curing throat and mouth diseases and a preparation method thereof. The preparation is prepared from watermelon frost, eucalyptus oil, peppermint oil, menthol, Fructus Terminaliae Immaturus, grosvenor momordica fruit, ophiopogon root, ladybell root, smoked plum, dried tangerine peel, borneol and licorice root. The preparation of the present invention has the efficiency of expelling wind, clearing heat, removing toxicity for detumescence, relieving sore-throat for alleviating pain and repelling foulness with aromatics, is mainly used for treating diseases, such as swelling and pain in throat due to wind and heat, dry throat, dry mouth, cough due to dryness and itching, hoarse voice, halitosis, acute pharyngitis, acute laryngitis, etc., and has the advantages of conspicuous curative effect and wide disease treatment spectra.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation and preparation method thereof, particularly relate to a kind of Chinese medicine preparation of preventing and treating throat and oral cavity diseases and preparation method thereof.
Background technology
Throat and oral cavity diseases belongs to traditional Chinese medical science categories such as " tonsillitis, sore throat, aphonia due to throat disease ", be subordinate to ability to speak, larynx section, diseases such as the said acute and chronic pharyngitis of modern medicine, acute tonsillitis, oral ulcer, stomatitis, gingival swelling and pain, pathogeny Chinese medicine is thought " all diseases of throat all belong to fire ", mainly be body diseases caused by exogenous pathogenic factor pyretic toxicity and cause on the pathogenic fire scorchingly, or cause exopathogen because oral cavity and throat is unclean and invade.Moreover be exactly that plain body loses void, and cause hyperactivity of deficient fire.Modern medicine study thinks that the scorching card of oral cavity and throat disease mainly is an infected by microbes such as antibacterial, virus and causing, or body immunity is low, and antibacterial, virus are in the pathogenic microorganism growth imbalance of oral cavity and throat and cause infection.Also have due to the mechanical damage simultaneously, or excessively take place with throat.This disease can repeatedly take place, and can often take place.The tradition Chinese medicine has much the commentary treatise of oral cavity throat disease, has also put down in writing many prescriptions, and as Yangyin Qingfei Tang, BINGPENG SAN etc., these prescriptions are to adopt according to concrete symptom, are the important component parts of Chinese medicine content.Ancient Chinese medicine medicine or Chinese medicine among the people are fully being summed up, excavating or utilized to the modern Chinese medicine theory also.Just introduce the many proved recipes of control oral cavity and throat diseases, typical prescription as Chinese medicine institution of higher learning teaching material " traditional Chinese medical science otolaryngology ", the control oral cavity and throat diseases is had directive function preferably.In recent years adopt some pharmaceutical factories and Chinese medicine research institution also releases some medicines, as clear and rich lozenge of the four seasons, folk song buccal tablet etc., but these Chinese medicine effects differ, the selling at exorbitant prices that has, and the specific aim that has is not strong, and curative effect is unsatisfactory.Chinese patent literature also discloses many medicines that prevent oral cavity and throat diseases as 9115242.5, a kind of Chinese medicine for the treatment of pharyngolaryngitis, by Chinese medicine Radix Achyranthis Bidentatae and Herba Houttuyniae through selecting materials pulverizing, sterilization, packed forming.99117145.4, disclosing a kind of pure medical herbs for the treatment of throat disease efficiently looses, 99120049.7, disclosing with beaver bile, Fructus Momordicae, Mentholum is primary raw material, be aided with gelatin, starch, glucose, stevioside, glycerol, potassium sorbate thick film sheet, for the usefulness that contains food through being processed into.01,128,346 1 kinds of health medicine and production methods thereof for the treatment of oral cavity and laryngopharyngeal diseases, it comprise Flos Lonicerae, Flos Chrysanthemi, Radix Isatidis, Herba Hedyotidis Diffusae, Radix Platycodonis, Periostracum Cicadae, Flos Ilicis Asprellae, Herba Taraxaci ,-raw material of Chinese medicine such as Radix Glycyrrhizae.The prescription too complex that the prescription of said medicine has, the curative effect that does not have production method, has that has are definite inadequately, and it is narrow to adapt to sick spectrum, thereby promote the use of and be subjected to certain restriction.
Summary of the invention
The object of the invention is to provide Chinese medicine preparation of the immoderate control throat and oral cavity diseases of a kind of determined curative effect, steady quality, safety and preparation method thereof.
The present invention seeks to be achieved through the following technical solutions:
Watermelon crystal 10～25 weight portions, Oleum Eucalypti 0.5～8 weight portion, Oleum menthae 0.5～8 weight portion, Mentholum (has another name called: 0.5～4 weight portion menthol), FRUCTUS TERMINALIAE IMMATURUS 20～60 weight portions, Fructus Momordicae 15～40 weight portions, Radix Ophiopogonis 15～35 weight portion, Radix Adenophorae 15～35 weight portions, Fructus Mume 20～62 weight portions, Pericarpium Citri Reticulatae 10～30 weight portions, Borneolum Syntheticum 0.5～4 weight portion, Radix Glycyrrhizae 5～20 weight portions, above-mentioned composition can add conventional adjuvant and make clinical acceptable forms, as buccal tablet, effervescent tablet, oral liquid, capsule, syrup, spray, granule, paster, drop pill etc.
Preparation technology:
1, gets the fragmentation respectively of FRUCTUS TERMINALIAE IMMATURUS, Fructus Momordicae, Radix Ophiopogonis, Radix Adenophorae, Fructus Mume, Pericarpium Citri Reticulatae, Radix Glycyrrhizae, mix, add 8～15 times of water, decocted 1～4 hour, medicinal residues 9～15 times of decoctings again boiled merge extractive liquid, 1～4 hour, be concentrated into relative density and be 1.15～1.45/60 ℃ extractum, adding ethanol is 50～90% to containing the alcohol amount, static 18～36 hours, gets supernatant, reclaim ethanol, add watermelon crystal, mix and be concentrated into the extractum A of 1.20～1.45/60 ℃ of relative densities, standby.
2, getting sucrose, also can be that sorbitol, mannitol, lactose etc. add suitable quantity of water heating and make dissolving, adds glucose syrup, can be starch syrup also, be concentrated into water content in the massecuite, add A less than 3%, mixing adds the mixture of Oleum Eucalypti, Oleum menthae, Mentholum, Borneolum Syntheticum and an amount of flavoring agent, mixing after cold slightly, molding, cooling, through film coating, packing, check gets product.
Watermelon crystal also can add in the massecuite in the 2nd step in the said method, mixes then.
Product watermelon crystal mouth larynx treasured of the present invention has been used an amount of saccharide, starch, flavoring agent in preparation process.Than good utilisation local genuine natural pharmaceutical resources prescription, at the control oral cavity and throat diseases unique curative effect is arranged, more favourable to implementing suitability for industrialized production simultaneously, be that sugar industry is in the bonded new formulation of pharmacy.This product curative effect affirms that mouthfeel is good, and melting time is long, also can continue medication, and is easy to carry about with one.Pharmaceutical composition of the present invention has the effect of wind and heat dispersing, removing toxic substances and promoting subsidence of swelling, relieving sore throat and pain, repelling foulness with aromatics, be mainly used in the laryngopharynx swelling and pain, dry mouth and throat, dried itching of wind heat and cough, hoarseness, diseases such as halitosis, acute pharyngitis, acute laryngitis, evident in efficacy, treat the disease spectrum width.
The watermelon crystal mouth larynx that pharmaceutical composition of the present invention is made is precious as being subjected to the following experimental example of reagent thing to be used to further specify the present invention.
Experimental example 1,The in-vitro antibacterial test
The Jia Xingrongxuexinglianqiujun that picking is fresh, B-mode A family Hemolytic streptococcus, each inoculating loop of staphylococcus aureus lawn, be inoculated in respectively among the suitable fluid medium 10ml, put 36 ± 1 ℃ and do for examination bacterium liquid (staphylococcus aureus is diluted to 1: 1000 with normal saline) after cultivating 24h.To be subjected to the reagent thing to do serial two-fold dilution respectively with each fluid medium, make and contain that crude drug concentration (W/V) is respectively 16%, 8%, 4%, 2%, 1% 0.5%, 0.25%, 0.125%, 0.0625% pastille culture medium, packing sterilization small test tube, every pipe 1ml.Each is inoculated in respectively in the corresponding serial pastille culture medium for examination bacterium liquid 0.1ml, puts 36 ± 1 ℃ and cultivate 24h.Get and respectively manage culture and change streak inoculation respectively on corresponding solid medium,, observe and have or not bacterial growth again by above-mentioned condition 24h.Be no more than 5 the highest drug dilution degree as the minimal inhibitory concentration (MIC) of this medicine with the growth bacterium colony.The results are shown in Table 1.Repeated trials once comes to the same thing.
Table 1 in-vitro antibacterial result of the test
Preceding drug level (the w: v) blank that plants
16% 8% 4% 2% 1% 0.25 0.25% 0.125% 0.0825% contrasts
Alpha streptococcus-----+++++
B-mode A family streptococcus-----+++++
Pacify yellow bacterium labor coccus-------+++
Annotate: "+" expression has bacterial growth; The no bacterial growth of "-" expression
As seen the result makes extracorporeal bacteria inhibitor test by doubling dilution, is subjected to the reagent thing that the MIC of Jia Xingrongxuexinglianqiujun, B-mode A family Hemolytic streptococcus is crude drug 1g%; MIC to staphylococcus aureus is crude drug 0.25g%.
Experimental example 2,Influence test to fever in rabbits due to the bacterial endotoxin
Get 32 of rabbit (♀ ♂ half and half), be divided into 4 groups at random.Measure each rabbit anus temperature 2 times with mercury clinical thermometer, the 1h of being separated by, with 2 anus using warming therapy averages as normal body temperature, administration subsequently: the high and low dose group is given and is subjected to the reagent thing, and positive controls is given aspirin compound, and the blank group is given ordinary water, dosage sees Table 2, the administration volume is 10ml/kg, and every day, the ig administration was 1 time, successive administration 2 days.After the last administration promptly through auricular vein bacterial injection endotoxin 50Eu/kg with pyrogenicity.Measure the anus temperature after the pyrogenicity at regular intervals once as being worth behind the medicine, the difference that subtracts normal value with value behind the medicine as medicine after the intensification value, with the ordinary water group relatively, the check of work group problem.The results are shown in Table 2.
Fever in rabbits influences result (C due to the table 2 pair bacterial endotoxin; X ± SD)
Intensification value behind the group dosage N normal body temperature medicine
(/kg) 1.5h 2.5h 3.5h 4.5h
The precious high 1.07g 8 38.52 of watermelon crystal mouth larynx ± 0.56 0.79 ± 0.35*, 0.64 ± 0.31*, 0.56 ± 0.47*, 0.33 ± 0.49*
The precious low 0.67g 8 38.75 of watermelon crystal mouth larynx ± 0.40 0.76 ± 0.30*, 0.46 ± 0.36*, 0.44 ± 0.42*, 0.13 ± 0.28*
This woods 0.54g 8 38.71 of compound recipe ± 0.56 0.35 ± 0.26**, 0.22 ± 0.37*, 0.39 ± 0.47*, 0.30 ± 0.49*
Ordinary water 10ml 8 38.40 ± 0.33 0.78 ± 0.36 0.67 ± 0.48 0.80 ± 0.42 0.41 ± 0.32
The result as seen, behind the medicine of the precious high and low dose group of watermelon crystal mouth larynx the intensification value all less than the ordinary water group, but difference there are no significant meaning.Seemingly point out this product that fever in rabbits due to the bacterial endotoxin is had certain refrigeration function trend.
Experimental example 3,The influence test of xylol induced mice auricle edema
Get 60 of ♂ mices, be divided into 5 groups and administration at random; Three groups are given and are subjected to the reagent thing, and the positive is given prednisone to former group, and the blank group is given ordinary water, and dosage sees Table 3, and the administration volume is 20ml/kg, and every day, 1g was administered once, continuous 5 days.1h after the last administration, be applied to the wide two sides of each Mus auris dextra so that scorching with dimethylbenzene 20ul. cause scorching back 30mln and put to death mice, cut left and right auricle, card punch with diameter 8mm is laid left and right garden auricle respectively at corresponding position, torsion balance (one thousandth) is weighed, the difference that deducts left auricle weight with auris dextra sheet rate compares with the ordinary water group as total expansibility (mg), the check of work group problem. the results are shown in Table 3.
The table 3 couple bullate result that influences of mice dimethylbenzene ear
Group dosage (/kg) n swelling degree (mg; The suppression ratio (%) of X ± SD)
The precious high 1.07g 12 5.5 ± 3.6*** 59.0 of watermelon crystal mouth larynx
0.67g 12 8.1 ± 4.7*** 39.6 in the watermelon crystal mouth larynx treasured
The precious low 0.33g 12 10.7 ± 4.7* 20.1 of watermelon crystal mouth larynx
Prednisone 20mg 12 2.3 ± 1.8*** 82.8
Ordinary water 20ml 12 13.4 ± 4.0
The result as seen, the auricle swelling degree of the precious high, medium and low dosage group of watermelon crystal mouth larynx is respectively less than ordinary water group 59.0% (P＜0.01), 39.6% (P＜0.01), 20.1% (P＞0.05). prompting this product has the effect that suppresses auricle edema due to the mice dimethylbenzene.
Experimental example 4,The influence test that capillary of skin permeability due to the rat histamine is increased
Get 50 of rats, ♀ ♂ half and half is divided into 5 groups and administration at random by body weight; Three groups are given and are subjected to the reagent thing, positive controls is given chlorphenamine, the blank group is given ordinary water, dosage sees Table 4, the administration volume is 10ml/kg, and every day, 1g was administered once, continuous 7 days. 1h after the last administration, be injected in each Mus back skin and flesh with histamine phosphate 100ug, and stamp in vena femoralis injection 1% azovan blue 4ml/kg.Put to death animal behind the 30min, cut back indigo plant and dye skin, be soaked in after shredding in acetone normal saline (7: the 3) mixed liquor, place 72h in 37 ℃ of water-baths.Soak is got supernatant and is measured its OD value in semiautomatic biochemistry analyzer 578nm wavelength place after centrifugal, with the amount that OD value representation azovan blue oozes out, reflects the permeability of capillary of skin indirectly.Compare the check of work group problem with the ordinary water group..The results are shown in Table 4.
The capillary of skin permeability increases due to the table 4 pair rat histamine influences the result
Group dosage (/kg) the N OD value (suppression ratio (%) of x ± SD)
The precious high 1.07g 10 0.267 ± 0.114*** 58.8 of watermelon crystal mouth larynx
0.67g 10 0.304 ± 0.109** 53.1 in the watermelon crystal mouth larynx treasured
The precious low 0.88g 10 0.367 ± 0.134** 43.4 of watermelon crystal mouth larynx
Chlorphenamine 5mg 10 0.152 ± 0.064*** 76.5
Ordinary water 20ml 10 0.648 ± 0.358
The result as seen, the OD value of the precious high, medium and low dosage group of watermelon crystal mouth larynx is respectively than ordinary water matched group reduction by 58.8% (P＜0.01), 53.1% (P＜0.05), 43.4% (P＜0.05).Prompting this product is to the effect that obvious suppression is arranged of increasing of capillary of skin permeability due to the rat histamine.
Experimental example 5,Influence test to mouse peritoneum chamber leukocyte (WBC) migration
Get 50 of ♂ mices, be divided into 5 groups and administration at random: three groups are given and are subjected to the reagent thing, and positive controls is given prednisone, and the blank group is given ordinary water, and dosage sees Table 5, and the administration volume is 20ml/kg, and every day, ig was administered once, continuous 5 days.50min after the last administration, the equal ip1.5%CMC-Na solution of every Mus 0.5ml.30min puts to death mice behind ip, and with 1% hydrochloric acid flushing abdominal cavity, collecting flushing liquor to final volume is 10ml, and the WBC number with in the microscope count method counting flushing liquor compares with the ordinary water group, the check of work group problem.The results are shown in Table 5
Table 5 pair mouse peritoneum chamber WBC migration influence the result
Group dosage (/kg) n WBC number (10
3/ L; X ± SD) raising rate (%)
The precious high 1.07g 10 7.590 ± 1.550*** 31.7 of watermelon crystal mouth larynx
0.67g 10 7.768 ± 1.339*** 34.7 in the watermelon crystal mouth larynx treasured
The precious low 0.38g 10 7.275 ± 0.886*** 26.2 of watermelon crystal mouth larynx
Prednisone 20mg 10 3.490 ± 0.716***-39.5
Ordinary water 20ml 10 5.765 ± 1.113
The result as seen, the WBC number average of the precious high, medium and low dosage group of watermelon crystal mouth larynx is higher than the ordinary water group, difference has the highly significant meaning.Prompting this product has certain facilitation to the mouse peritoneum chamber WBC migration that CMC-Na brings out.
Experimental example 6,The influence test that the mice hot plate is caused pain is got the prediction pain threshold 60 of the ♀ mices of 14-23 second (assay method is seen below), measure twice pain threshold before the administration: it is that 55 ± 0.5 ℃ hot plate causes in the pain instrument can that mice is dropped into baseplate temp, with drop into from mice hot plate to its time of adding metapedes as the wealthy value of pain, two minor tick 30min take second place all as the wealthy value of normal pain with two.Mice is divided into 5 groups and administration at random by the wealthy value size of pain; Three groups are given and are subjected to the reagent thing, and positive controls is given aspirin phenacetin caffeine, and the blank group is given ordinary water, and dosage sees Table 6, and the administration volume is 20ml/kg.60min, 120min, 180min measure the wealthy value of pain of each Mus respectively with method after administration, the difference that deducts normal value with value behind the medicine as medicine after the wealthy increment of pain, with the ordinary water group relatively, check as problem.The results are shown in Table 6.
Table 6 pair mice hot plate cause the pain influence the result (second; X ± SD)
Threshold of pain increment behind the normal pain threshold medicine of group n dosage
(/kg) 60min 120min 180min
Precious high 12 1.07g 18.2 of watermelon crystal mouth larynx ± 3.0 4.63 ± 3.46**, 6.29 ± 5.51***, 4.82 ± 5.50**
12 0.67g 18.3 in the watermelon crystal mouth larynx treasured ± 2.7 3.40 ± 4.55**, 4.58 ± 4.30***, 3.31 ± 6.62*
Precious low 12 0.33g 18.3 of watermelon crystal mouth larynx ± 2.7 1.23 ± 3.72*, 3.05 ± 4.83*, 0.84 ± 2.59*
Aspirin compound 12 0.23g 18.4 ± 2.9 5.92 ± 2.38***, 9.56 ± 6.32***, 8.84 ± 8.46***
Ordinary water 12 20ml 18.4 ± 3.0-0.07 ± 3.38-0.97 ± 5.12-1.03 ± 5.11
The result as seen, the wealthy value of pain is all greater than the ordinary water group behind the medicine of the precious high, medium and low dosage group of watermelon crystal mouth larynx, the difference of high, middle dosage group and ordinary water group has the significance meaning.Prompting this product causes pain to the mice hot plate certain analgesic activity.
Experimental example 7,Mice ammonia is drawn the influence test of coughing
Get 55 of mices, ♀ ♂ dual-purpose is divided into 5 groups and administration at random; Three groups are given and are subjected to the reagent thing, and positive controls is given and can be treated that together, the blank group is given ordinary water, and dosage sees Table 7, and the administration volume is 20ml/kg, and every day, 1g was administered once, continuous 5 days (positive controls only is administered once).1h after the last administration places constant voltage ammonia mist to draw to cough device to draw as ammonia each Mus and coughs: the time interval that the ammonia mist stimulates is 0.8, stimulate certain hour with ammonia spraying after, take out mice immediately, observe and having or not the cough reaction in the 1min, positive with cough in the 1min 3 times.Obtain the spray time (EDT that causes the half mouse cough with " sequential method "
00).Calculate the R value by following formula, estimate the antitussive effect intensity that is subjected to the reagent thing.The results are shown in Table 7.
Table 7 pair mice ammonia draws the result that influences who coughs
Group N dosage EDT
00The R value
(/kg) (second) (%)
Precious high 11 1.07g 42.4 148.8 of watermelon crystal mouth larynx
11 0.07g 41.5 145.8 in the watermelon crystal mouth larynx treasured
Precious low 11 0.33g 32.3 113.3 of watermelon crystal mouth larynx
Codeine 11 60mg 45.1 158.2
Ordinary water 11 20ml 28.5
The result as seen, the R value of the precious high and low dose group of watermelon crystal mouth larynx is all greater than 130%.Point out this product that mice ammonia is drawn and cough certain antitussive action.
Embodiment 1:
Watermelon crystal 12 restrains, Oleum Eucalypti 4 restrains, Oleum menthae 4 restrains, Mentholum 2 restrains, FRUCTUS TERMINALIAE IMMATURUS 30 restrains, Fructus Momordicae 25 restrains, restrain Radix Ophiopogonis 25, Radix Adenophorae 25 restrains, Fructus Mume 42 restrains, Pericarpium Citri Reticulatae 15 restrains, Borneolum Syntheticum 2 restrains, Radix Glycyrrhizae 15 restrains
It is broken respectively to get FRUCTUS TERMINALIAE IMMATURUS 30g, Fructus Momordicae 25g, Radix Ophiopogonis 25g, Radix Adenophorae 25g, Fructus Mume 42g, Pericarpium Citri Reticulatae 15g, Radix Glycyrrhizae 15g, mixes, and adds 10 times of water, decocted 2.5 hours, medicinal residues decocted 12 hours again, merge extractive liquid,, be concentrated into relative density and be 1.22/60 ℃ extractum, adding ethanol is 65% to containing the alcohol amount, static 24 hours, gets supernatant, reclaim ethanol, add watermelon crystal 20g, mix and be concentrated into the extractum A of 1.30/60 ℃ of relative density, standby.Sucrose adds the suitable quantity of water heating makes dissolving, adds glucose syrup, and the moisture content that is concentrated in the massecuite contains 2.01%, add A, mixing adds the mixture of Oleum Eucalypti 4g, Oleum menthae 4g, Mentholum 2g, Borneolum Syntheticum 2g and an amount of spice, mixing after cold slightly, molding, cooling, through film coating, packing, check gets product 1000.
Claims (7)
1, a kind of Chinese medicine composition of preventing and treating throat and oral cavity diseases is characterized in that said composition made by following crude drug:
Watermelon crystal 10～25 weight portion Oleum Eucalyptis 0.5～8 weight portion Oleum menthae 0.5～8 weight portion
Mentholum 0.5～4 weight portion FRUCTUS TERMINALIAE IMMATURUS 20～60 weight portion Fructus Momordicaes 15～40 weight portions
Radix Ophiopogonis 15～35 weight portion Radix Adenophoraes, 15～35 weight portion Fructus Mumes, 20～62 weight portions
Pericarpium Citri Reticulatae 10～30 weight portion Borneolum Syntheticums 0.5～4 weight portion Radix Glycyrrhizae 5～20 weight portions.
2, Chinese medicine composition as claimed in claim 1 is characterized in that said composition made by following crude drug:
Watermelon crystal 12 weight portion Oleum Eucalyptis 4 weight portion Oleum menthaes 4 weight portions
Mentholum 2 weight portion FRUCTUS TERMINALIAE IMMATURUS 30 weight portion Fructus Momordicaes 25 weight portions
Radix Ophiopogonis 25 weight portion Radix Adenophoraes, 25 weight portion Fructus Mumes, 42 weight portions
Pericarpium Citri Reticulatae 15 weight portion Borneolum Syntheticums 2 weight portion Radix Glycyrrhizaes 15 weight portions.
3, Chinese medicine composition as claimed in claim 1 or 2 is characterized in that said composition adds the dosage form that conventional adjuvant is made clinical acceptance.
4, Chinese medicine composition as claimed in claim 3 is characterized in that said composition adds conventional adjuvant and makes arbitrary dosage form in buccal tablet, effervescent tablet, oral liquid, capsule, syrup, spray, granule, paster or the drop pill.
5, the preparation method of Chinese medicine composition as claimed in claim 1 or 2 is characterized in that this method is:
It is broken respectively to get FRUCTUS TERMINALIAE IMMATURUS, Fructus Momordicae, Radix Ophiopogonis, Radix Adenophorae, Fructus Mume, Pericarpium Citri Reticulatae, Radix Glycyrrhizae, mixes, and adds 8～15 times of water, decocted 1～4 hour, medicinal residues 9～15 times of decoctings again boiled merge extractive liquid, 1～4 hour, be concentrated into relative density and be 1.15～1.45/60 ℃ extractum, adding ethanol is 50～90% to containing the alcohol amount, static 18～36 hours, gets supernatant, reclaim ethanol, add watermelon crystal, mix and be concentrated into the extractum A of 1.20～1.45/60 ℃ of relative densities, standby; Get sucrose, add the suitable quantity of water heating and make dissolving, add glucose syrup, be concentrated into water content in the massecuite less than 3%, add A, mixing, the mixture that adds Oleum Eucalypti, Oleum menthae, Mentholum, Borneolum Syntheticum and an amount of flavoring agent after cold slightly, mixing, molding, cooling, through film coating, packing, check gets product.
6, the preparation method of Chinese medicine composition as claimed in claim 5 is characterized in that this method is:
It is broken respectively to get FRUCTUS TERMINALIAE IMMATURUS, Fructus Momordicae, Radix Ophiopogonis, Radix Adenophorae, Fructus Mume, Pericarpium Citri Reticulatae, Radix Glycyrrhizae, mixes, and adds 10 times of water, decocted 2.5 hours, medicinal residues decocted 12 hours again, merge extractive liquid,, be concentrated into relative density and be 1.22/60 ℃ extractum, adding ethanol is 65% to containing the alcohol amount, static 24 hours, gets supernatant, reclaim ethanol, add watermelon crystal, mix and be concentrated into the extractum A of 1.30/60 ℃ of relative density, standby; Sucrose adds the suitable quantity of water heating makes dissolving, adds glucose syrup, and the moisture content that is concentrated in the massecuite contains 2.01%, adds A, mixing, the mixture that adds Oleum Eucalypti, Oleum menthae, Mentholum, Borneolum Syntheticum and an amount of spice after cold slightly, mixing, molding, cooling, through film coating, packing, check gets product.
7,, it is characterized in that the sucrose in this method is replaced by sorbitol, mannitol or lactose as the preparation method of claim 5 or 6 described Chinese medicine compositions; Glucose syrup is replaced by starch syrup.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021573786A CN1191848C (en) | 2002-12-23 | 2002-12-23 | Chinese medicine prepn for treating throat diseases and stomatopathy and its prepn process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021573786A CN1191848C (en) | 2002-12-23 | 2002-12-23 | Chinese medicine prepn for treating throat diseases and stomatopathy and its prepn process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1421240A CN1421240A (en) | 2003-06-04 |
| CN1191848C true CN1191848C (en) | 2005-03-09 |
Family
ID=4752954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021573786A Expired - Lifetime CN1191848C (en) | 2002-12-23 | 2002-12-23 | Chinese medicine prepn for treating throat diseases and stomatopathy and its prepn process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1191848C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109953170A (en) * | 2019-04-17 | 2019-07-02 | 桂林三金大健康产业有限公司 | A kind of sugar-free type water melon frost throat clearing and moistening sugar and its preparation method and application |
| CN109997947A (en) * | 2019-04-17 | 2019-07-12 | 桂林三金大健康产业有限公司 | Water melon frost throat clearing and moistening sugar and its preparation method and application |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20032287A1 (en) * | 2003-11-24 | 2005-05-25 | Indena Spa | COMPOSITIONS FOR THE TREATMENT OF THE ORAL CABLE AFFECTIONS AND THE FIRST RESPIRATORY ROUTES |
| CN1308004C (en) * | 2003-12-31 | 2007-04-04 | 中山市恒生药业有限公司 | Pepper mint eucalyptus lozenge and its preparation method |
| CN101020009B (en) * | 2007-03-05 | 2010-05-19 | 广东南台药业有限公司 | Medicated teafor clearing away heat of pharynx and larynx |
| CN105796865A (en) * | 2014-12-30 | 2016-07-27 | 桂林三金药业股份有限公司 | Lozenge for clearing heat from throat and preparation method thereof |
| CN104622946A (en) * | 2015-01-12 | 2015-05-20 | 福建农林大学 | Gynura bicolor heat-clearing buccal tablet and preparation method thereof |
-
2002
- 2002-12-23 CN CNB021573786A patent/CN1191848C/en not_active Expired - Lifetime
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109953170A (en) * | 2019-04-17 | 2019-07-02 | 桂林三金大健康产业有限公司 | A kind of sugar-free type water melon frost throat clearing and moistening sugar and its preparation method and application |
| CN109997947A (en) * | 2019-04-17 | 2019-07-12 | 桂林三金大健康产业有限公司 | Water melon frost throat clearing and moistening sugar and its preparation method and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1421240A (en) | 2003-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1244361C (en) | Medicinal composition for curing oral and throa diseases and its preparing method, use and quality control method | |
| CN1127648A (en) | Chinese medicine composition with antipyretic and antidote functions and use thereof | |
| CN1210047C (en) | Medicine for treating cold and preparation method thereof | |
| CN1191848C (en) | Chinese medicine prepn for treating throat diseases and stomatopathy and its prepn process | |
| CN1927160A (en) | Gargle and its preparing process | |
| CN104096047A (en) | Externally-applied detoxification ointment for treatment of poisonous snake bite wound and preparation method thereof | |
| CN108686009A (en) | Prevent and/or treat essential oil composition, preparation method, application and the preparation of rhinitis | |
| CN1151823C (en) | Medicine for preventing and treating cold and its preparing process | |
| CN1954866A (en) | Medicine for treating odontopathy and its preparation method | |
| CN105497133A (en) | Periplaneta Americana medicine composition for treating pharyngitis and tonsillitis and preparation method thereof | |
| CN1283391A (en) | Extracted liquor for disinfection | |
| CN100350948C (en) | Compound throat sucking-tablet of semen sterculiae scaphigerae and oral tonic thereof | |
| CN107669956A (en) | Treat dog, the Chinese medicine preparation and preparation method thereof of cat otopathy | |
| CN102885930B (en) | Externally applied cream for treating toothache caused by heat | |
| CN107648494A (en) | One kind treats gingivitis and canker sore Chinese medical collutory and preparation method thereof | |
| CN101606985A (en) | A liniment for treating sheep infectious impetigo virus and its preparation method | |
| CN1686239A (en) | Antivirus gel preparation and its preparation method | |
| CN104825852A (en) | Tibetan medicine composition, preparation method and application thereof | |
| CN110025685B (en) | A liquid preparation containing propolis composition | |
| CN1631389A (en) | Medicine for treating acute and chronic pharyngitis and its preparing process | |
| CN104739922A (en) | Traditional Chinese medicine kaihoujian mouth wash and preparation method thereof | |
| CN103908580A (en) | Traditional Chinese medicinal buccal tablet for treating amygdalitis and preparation method thereof | |
| CN114146125B (en) | Traditional Chinese medicine composition for inhibiting helicobacter pylori infection in oral cavity | |
| CN104490948A (en) | Pharmaceutical composition for treating chronic periodontitis and preparation method thereof | |
| CN104524305A (en) | Mouth wash relieving toothache and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| ASS | Succession or assignment of patent right |
Owner name: GUILIN SANJIN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZOU JIEMING Effective date: 20031010 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20031010 Applicant after: GUILIN SANJIN PHARMACEUTICAL Co.,Ltd. Applicant before: Zou Jieming |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20050309 |
|
| CX01 | Expiry of patent term |